イシュケミアと非阻害性冠動脈疾患 (INOCA): 証拠に基づいた治療法と次の10年間の研究計画の開発
C Noel Bairey Merz1, Carl J Pepine2, Mary Norine Walsh2
1From Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Los Angeles, CA (C.N.B.M.); Division of Cardiology, University of Florida, Gainesville (C.J.P.); St. Vincent Heart Transplant, Indianapolis, IN (M.N.W.); and National Heart, Lung, and Blood Institute, Bethesda, MD (J.L.F.). merz@cshs.org.
Circulation
|March 15, 2017
まとめ
閉塞性冠動脈がない心筋不全の患者は,心血管疾患のリスクが高くなります. このコンセンサスレポートは統合管理戦略を概説し,この状態に関する研究のギャップを特定しています.
科学分野:
- 心臓病科
- 心血管研究
背景:
- 閉塞性冠動脈のない心筋梗塞症 (INOCA) は重要な患者集団に影響します.
- 急性冠動脈症候群および心不全を含む心血管不良のリスクが増加します.
- INOCA患者のサブセットは冠動脈微小血管機能障害と炎症を呈している.
研究 の 目的:
- 閉塞性冠動脈のない心筋不全症候群に関するコンセンサスを形成する.
- INOCA患者さんを特定し,治療するための統合的アプローチを推奨する.
- 知識のギャップを概説し,将来の研究方向を提案する.
主な方法:
- 主要な循環器組織の代表者を含む作業部会を招集した.
- リスク評価のための利用可能な文献と現在の実践を批判的に検討した.
- 最先端の科学技術と 根拠に基づいた治療の開発に焦点を当てた
主要な成果:
- INOCAを服用している患者は,心血管疾患や心不全のリスクが高まります.
- 冠動脈微小血管機能障害と炎症は,INOCA患者のサブグループに存在する.
- INOCAの管理を進めるために,将来の研究のための重要な分野を特定しました.
結論:
- INOCAの特定と管理には統合されたアプローチが必要である.
- INOCAの根拠に基づいた治療法を開発するには,さらなる研究が不可欠です.
- 知識のギャップを埋めることで,INOCA患者の治療結果が改善されます.
関連する概念動画
Ischemic Heart Disease: Overview
3.7K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.7K
Coronary Artery Disease V: Interprofessional Care
354
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
354
Acute Coronary Syndrome IV: Interprofessional Care
358
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
358
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
590
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
590
Angina IV: Management
368
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
368
Coronary Artery Disease II: Pathophysiology
847
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
847


